KNOWPIA
WELCOME TO KNOWPIA
FOLLOWING：0FOLLOWERS：0
kdoe06388@gmail.com
Author Popular Blog
Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 – Roots Analysis
2021-03-29 23:55
To order this detailed 500+ page report, please visit this -https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.htmlKey Inclusions§
A det
More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy – By Roots Analysis
2021-03-29 23:51
There is a growing body of evidence supporting the vast
applicability and superiority of treatment outcomes of stem cell therapies,
compared to conventional t
The stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030 - Roots Analysis
2021-03-29 23:47
Roots Analysis has done a detailed
study on “Global Stem Cells
Market:
Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic,
Autologo
With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030 - By Roots Analysis
2021-03-29 23:42
With multiple approved products, the field of stem cell
therapies has gained substantial momentum over the last decade; several
innovator companies are curren
“HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030”
2021-03-26 00:05
To order this detailed 300+ page report, please visit this -
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.ht
Close to 120 companies across the globe claim to possess the required expertise / Roots Analysis
2021-03-26 00:01
Development initiatives
of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of
experience and capital investment. Most companies general
Growing at an annualized rate of 12%, the HPAPI is projected to reach USD 25 billion by 2030, By Roots Analysis
2021-03-25 23:57
Roots Analysis has done a detailed study on “HPAPI
and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.” covering key
aspects of the industry’s evolutio
Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market / Roots Analysis
2021-03-25 23:51
Manufacturing highly potent drug products is technically and financially
demanding; as a result, drug manufacturers are becoming increasingly reliant on
contr
“Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030”
2021-03-25 23:44
To order this 170+ page report, please visit
this
- https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.htmlKey
Inclusions§
Over 85 firms are involved in providing fragment-based drug discovery-related services
2021-03-25 23:40
According to experts
in this field, fragment-based drug discovery solutions have facilitated the identification
of viable pharmacological leads against otherw
The fragment-based drug discovery market is projected to grow at an annualized rate of ~10%, till 2030 / By roots Analysis
2021-03-25 23:36
Roots Analysis has done a detailed study on Fragment-based Drug Discovery Market: Library and
Service Providers, 2020-2030”, covering key
aspects of the indus
Fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030, By Roots Analysis
2021-03-25 23:30
Screening small molecule fragments has made it possible to identify
pharmacological leads against otherwise hard to target hotspots on
biomolecules, such as a
Growing at an annualized rate of 10%, the fragment-based drug discovery market / ByRoots Analysis
2021-03-25 23:25
Traditional drug discovery is associated with exorbitant
investments, prolonged lead evolution timelines and high attrition rates; the
fragment-based approach
‘Patient Recruitment and Retention Services, 2019-2030’
2021-03-25 00:30
To order this detailed 300+ page report, please visit this -
https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-mar
Presently, close to 140 companies claim to be actively engaged in offering patient recruitment / By Roots Analysis
2021-03-25 00:27
A steadily increasing demand for study participants and the
complexities associated with patient enrollment has imposed a significant
burden on drug developer